ArticleEJIFCC2026
Impact of Hemolysis on UCH-L1 Quantification in Serum and Plasma.
Article in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is a neuron-enriched deubiquitinase widely used for the evaluation of mild traumatic brain injury (TBI). Although minimal hemolysis-related interference has been reported for the Abbott TBI assay, routine laboratory observations indicate that hemolysis may substantially influence UCH-L1 measurements. This study aimed to evaluate the effect of hemolysis on UCH-L1 concentrations in plasma and serum samples and its potential clinical implications. Methods: Hemolysis interference was evaluated in accordance with CLSI C56-A and EP07 guidelines using pooled plasma samples and paired individual patient samples. Controlled hemolysis was induced by adding graded amounts of erythrocyte hemolysate to non-hemolyzed samples. UCH-L1 concentrations were measured using the Abbott Alinity i system. In addition, a retrospective analysis of routine TBI biomarker requests was conducted to estimate the potential rate of hemolysis-induced false-positive results. Results: In pooled plasma, UCH-L1 increased linearly (R Conclusions: Hemolysis induces a clinically relevant positive bias in UCH-L1 measurements, even at moderate HI levels. These findings underscore the importance of strict preanalytical control and cautious interpretation of UCH-L1 results obtained from hemolyzed samples.
Indexed as
Identifiers
42729666PMC13563521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.